Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ANAB 
AnaptysBio Inc (ANAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: ANAB (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $63.91
1 Year Target Price $63.91
| 7 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 49.38% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.25B USD | Price to earnings Ratio - | 1Y Target Price 63.91 |
Price to earnings Ratio - | 1Y Target Price 63.91 | ||
Volume (30-day avg) 12 | Beta 0.29 | 52 Weeks Range 12.21 - 46.56 | Updated Date 12/9/2025 |
52 Weeks Range 12.21 - 46.56 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.82 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -49.94% | Operating Margin (TTM) 45.47% |
Management Effectiveness
Return on Assets (TTM) -4.23% | Return on Equity (TTM) -308.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 993633644 | Price to Sales(TTM) 7.35 |
Enterprise Value 993633644 | Price to Sales(TTM) 7.35 | ||
Enterprise Value to Revenue 5.86 | Enterprise Value to EBITDA -1.3 | Shares Outstanding 27688470 | Shares Floating 14357579 |
Shares Outstanding 27688470 | Shares Floating 14357579 | ||
Percent Insiders 5.76 | Percent Institutions 114.11 |
Upturn AI SWOT
AnaptysBio Inc
Company Overview
History and Background
AnaptysBio Inc. was founded in 2005 with the mission to develop antibody-based therapeutics. A significant milestone was its initial public offering (IPO) in 2014. The company has evolved to focus on developing novel antibody therapeutics for inflammatory diseases and oncology, often utilizing its proprietary platform technologies.
Core Business Areas
- Inflammatory Diseases: AnaptysBio is developing antibody therapies targeting key inflammatory pathways for diseases such as atopic dermatitis, hidradenitis suppurativa, and psoriasis. These programs aim to provide differentiated treatment options for patients with significant unmet needs.
- Oncology: The company is also exploring antibody-based approaches for cancer treatment, though its primary focus has been on inflammatory indications. This segment may involve collaborations or internal development of novel oncology targets.
Leadership and Structure
AnaptysBio Inc. is led by a management team comprising experienced professionals in biotechnology and drug development. The organizational structure is typical of a clinical-stage biopharmaceutical company, with departments dedicated to research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Etokimab (AN001): An investigational antibody targeting the interleukin-33 (IL-33) pathway. It has been evaluated for atopic dermatitis and eosinophilic esophagitis. Market share data is not applicable as it is an investigational drug. Competitors include companies developing biologics targeting other inflammatory cytokines or pathways, such as Dupixent (Sanofi/Regeneron) for atopic dermatitis.
- AN002 (Tizaaul): An investigational antibody targeting the TSLP pathway, evaluated for atopic dermatitis. Similar to Etokimab, market share is not applicable. Competitors include companies developing TSLP inhibitors or other biologic therapies for atopic dermatitis.
- ANB030 (Itepekimab): An antibody targeting the IL-33 pathway, partnered with GSK for severe atopic dermatitis. Market share not applicable. Competitors are similar to those for Etokimab.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the immunology and oncology space, is characterized by rapid innovation, significant R&D investment, and a complex regulatory landscape. There is a strong demand for novel therapeutics that offer improved efficacy, safety, and convenience.
Positioning
AnaptysBio is positioned as an emerging biopharmaceutical company focused on developing differentiated antibody therapeutics. Its competitive advantages lie in its proprietary antibody discovery platform and its pipeline of novel drug candidates targeting key inflammatory pathways.
Total Addressable Market (TAM)
The TAM for inflammatory diseases like atopic dermatitis, psoriasis, and hidradenitis suppurativa is substantial, estimated to be in the tens of billions of dollars globally. AnaptysBio is positioned to capture a portion of this TAM with its pipeline, though it faces competition from established players and other emerging companies.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery and engineering platform.
- Pipeline of novel antibody candidates targeting inflammatory diseases.
- Experienced management team with a track record in drug development.
- Strategic partnerships (e.g., with GSK).
Weaknesses
- Reliance on clinical trial success for pipeline progression.
- Limited commercialization experience as a standalone company.
- High R&D costs and long development timelines.
- Potential for manufacturing complexities with antibody therapeutics.
Opportunities
- Growing market demand for innovative treatments for inflammatory diseases.
- Potential for licensing or acquisition by larger pharmaceutical companies.
- Expansion of pipeline into new therapeutic areas or indications.
- Advancements in antibody engineering technologies.
Threats
- Clinical trial failures or delays.
- Competition from existing and pipeline therapies.
- Regulatory hurdles and pricing pressures.
- Changes in healthcare policy and reimbursement.
Competitors and Market Share
Key Competitors
- Regeneron Pharmaceuticals, Inc. (REGN)
- Sanofi S.A. (SNY)
- AbbVie Inc. (ABBV)
- Eli Lilly and Company (LLY)
- Amgen Inc. (AMGN)
Competitive Landscape
AnaptysBio's advantages lie in its focused approach to specific inflammatory pathways and its proprietary antibody platform. However, it faces disadvantages against larger, more established competitors with broader portfolios, greater financial resources, and existing commercial infrastructure. Success hinges on demonstrating superior efficacy and safety profiles for its investigational therapies.
Growth Trajectory and Initiatives
Historical Growth: AnaptysBio's historical growth has been characterized by progress in its pipeline development, successful fundraising rounds, and strategic collaborations. Its evolution from a discovery-stage company to one with multiple clinical-stage assets represents its growth.
Future Projections: Future growth projections are contingent on the successful clinical development and potential regulatory approval of its pipeline candidates. Analyst estimates would typically focus on potential peak sales of key programs and the overall valuation of the company based on its R&D progress.
Recent Initiatives: Recent initiatives likely include advancing its lead drug candidates through clinical trials, exploring new indications for existing programs, and potentially forging new strategic partnerships or licensing agreements to expand its pipeline or leverage its technology.
Summary
AnaptysBio Inc. is a clinical-stage biopharmaceutical company with a promising pipeline of antibody-based therapeutics for inflammatory diseases. Its strengths lie in its proprietary technology and focused R&D. However, it faces significant risks associated with clinical trial outcomes and intense competition from established players. Success hinges on de-risking its pipeline through positive clinical data and securing strategic partnerships for future commercialization.
Similar Stocks
Sources and Disclaimers
Data Sources:
- AnaptysBio Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Biopharmaceutical Industry Market Research Reports
- Financial News and Analysis Websites
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Stock performance and market share data are subject to change. Readers should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AnaptysBio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2017-01-26 | President, CEO & Director Mr. Daniel R. Faga | ||
Sector Healthcare | Industry Biotechnology | Full time employees 136 | Website https://www.anaptysbio.com |
Full time employees 136 | Website https://www.anaptysbio.com | ||
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.